Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 19;31(3):155-161.
doi: 10.1055/s-0042-1750329. eCollection 2022 Sep.

Contemporary Treatment of Pulmonary Embolism: Medical Treatment and Management

Stephen Moreland  1 , Debabrata Mukherjee  1 , Nils P Nickel  1
Affiliations

Contemporary Treatment of Pulmonary Embolism: Medical Treatment and Management

Stephen Moreland et al. Int J Angiol. .

Abstract

Pulmonary embolus (PE) is defined as obstruction of the pulmonary artery or one of its branches by material (e.g., thrombus, tumor, air, or fat) but most commonly due to thrombus originating from the lower extremity deep veins. We reviewed the current literature describing the optimal medical treatment and management of PE. Databases (PubMed, the Cochrane Library, Embase, EBSCO, Web of Science, and CINAHL) were searched for relevant studies and guidelines for management of patients with PE. The initial approach to patients with suspected PE should focus upon stabilizing the patient while further workup for risk stratification is in progress. In most cases, anticoagulation should ideally be started even prior to confirming PE, if risk-benefit regarding suspicion of PE and bleeding risk is favorable. Once the diagnosis is confirmed, risk stratification will guide further therapies consisting of anticoagulation, thrombolysis, or catheter-directed interventions. Data for initial, long-term, and indefinite anticoagulation, and factors that determine whether or not a patient can be treated in the outpatient setting, are reviewed and discussed.

Keywords: anticoagulation; pharmacotherapy; pulmonary embolism; risk stratification; thrombolytic.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Authors confirm that they have no conflicts of interest.

References

    1. Tsao C W, Aday A W, Almarzooq Z I. Heart Disease and Stroke Statistics-2022 update: a report from the American Heart Association. Circulation. 2022;145(08):e153–e639. - PubMed
    1. Smith S B, Geske J B, Maguire J M, Zane N A, Carter R E, Morgenthaler T I. Early anticoagulation is associated with reduced mortality for acute pulmonary embolism. Chest. 2010;137(06):1382–1390. - PMC - PubMed
    1. Porres-Aguilar M, Anaya-Ayala J E, Jiménez D, Mukherjee D. Pulmonary embolism response teams: pursuing excellence in the care for venous thromboembolism. Arch Med Res. 2019;50(05):257–258. - PubMed
    1. Porres-Aguilar M, Anaya-Ayala J E, Mukherjee D, Tapson V F. Pulmonary embolism response teams in the challenging era of venous thromboembolism associated with COVID-19. J Vasc Surg Venous Lymphat Disord. 2020;8(05):898–899. - PMC - PubMed
    1. Porres-Aguilar M, Jiménez D, Porres-Muñoz M, Mukherjee D. Pulmonary embolism response teams: purpose, evidence for efficacy, and future research directions. Res Pract Thromb Haemost. 2019;3(04):769. - PMC - PubMed